Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994)

被引:27
作者
Ciatto, S
Gervasi, G
Bonardi, R
Frullini, P
Zendron, P
Lombardi, C
Crocetti, E
Zappa, M
机构
[1] Ctr Studio & Prevenz Oncol, I-50131 Florence, Italy
[2] Torre Galli Hosp, Dept Urol, Florence, Italy
关键词
prostate cancer; screening; overdiagnosis;
D O I
10.1016/j.ejca.2004.09.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The rate of overdiagnosis of prostate carcinoma was assessed by following 6890 participants in pilot screening studies from 1991 to 1994. Observed/expected incidence and mortality were determined using data from the Cancer and Mortality Registry. The cancer detection rate (1.75%) and observed/expected ratio (12.5:1) were high at the first screening, and substantially lower at the second screening (0.65% or 4.10:1). According to the registry follow-up, prostate cancer occurred in 225 subjects in the whole study cohort, while 178.2 were expected with 50 652 men/years at risk. The standardised incidence rate was 1.66 in the screened (95%CI = 1.4-2.0), 0.97 in the non-responders (95%CI = 0.8-1.2) and 1.23 in subjects excluded from invitation due to previous cancer or major illness (95%CIl = 0.8-1.5). A 66% excess incidence rate was observed in the screened subjects over a 9-year period, confirming previous estimates of overdiagnosis. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:411 / 415
页数:5
相关论文
共 15 条
  • [1] Alexander FE, 1999, EUR J CANCER, V35, P262
  • [2] COMPARING 2 MODALITIES OF SCREENING FOR PROSTATE-CANCER - DIGITAL RECTAL EXAMINATION PLUS TRANSRECTAL ULTRASONOGRAPHY VS PROSTATE-SPECIFIC ANTIGEN
    CIATTO, S
    BONARDI, R
    MAZZOTTA, A
    LOMBARDI, C
    SANTONI, R
    CARDINI, S
    ZAPPA, M
    [J]. TUMORI, 1995, 81 (04) : 225 - 229
  • [3] Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening
    Ciatto, S
    Zappa, M
    Bonardi, R
    Gervasi, G
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) : 1347 - 1350
  • [4] Cooper GS, 2001, CANCER, V92, P102, DOI 10.1002/1097-0142(20010701)92:1<102::AID-CNCR1297>3.0.CO
  • [5] 2-I
  • [6] Prostate cancer: Different incidence but not mortality trends within two areas of Tuscany, Italy
    Crocetti, E
    Ciatto, S
    Zappa, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (11): : 876 - 877
  • [7] Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
    de Koning, HJ
    Auvinen, A
    Sanchez, AB
    da Silva, FC
    Ciatto, S
    Denis, L
    Gohagan, JK
    Hakama, M
    Hugosson, J
    Kranse, R
    Nelen, V
    Prorok, PC
    Schröder, FH
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) : 237 - 244
  • [8] DRAISMA G, 2003, J NATL CANCER I, V595, P8688
  • [9] Etzioni R, 2002, J NATL CANCER I, V94, P981
  • [10] The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States
    Legler, JM
    Feuer, EJ
    Potosky, AL
    Merrill, RM
    Kramer, BS
    [J]. CANCER CAUSES & CONTROL, 1998, 9 (05) : 519 - 527